Related Experiment Video
Updated: Jun 17, 2025
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
A Pragmatic Approach to Introducing Translational Geroscience Into the Clinic: A Paradigm Based on the Incremental
Daniel E Forman1, Robert J Pignolo2
1Department of Medicine, Geriatrics and Cardiology, University of Pittsburgh and Pittsburgh Geriatrics, Research, and Clinical Center (GRECC), VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
Abstract:
Geroscience posits that molecular drivers underlie the aging process. Gerotherapeutics entail strategies to counter molecular drivers of aging to reduce the chronic diseases and geriatric syndromes they trigger. Although the concept of gerotherapeutics for prevention has generated much excitement, the implications of prescribing potentially harmful medications to older adults who are "healthy" have been associated with many delays. Concerns regarding safety and valid endpoints have contributed to holdups. In contrast, it has been relatively easier to implement trials of medications with gerotherapeutic properties as novel approaches to remedy disease. In these applications, the risks of the medications are easier to justify when therapeutic benefits are perceived as outweighing the harms of the disease. Likewise, metrics of effective disease treatments are often seen as more reliable and quantifiable than metrics of health prolongation. Overall, clarifying geroscience mechanisms in disease therapeutic applications provides key opportunities to advance translational geroscience, especially as preventive geroscience trials are often encumbered. In this review, gerotherapeutic benefits of canakinumab, cholchicine, and zoledronic acid as parts of disease management are considered. Longevity Clinics and other opportunities to advance translational geroscience as parts of contemporary care are also discussed.
Insights
Gerotherapeutics aim to counter aging's molecular drivers, reducing age-related diseases. While preventive applications face hurdles, using gerotherapeutic drugs for existing diseases is more feasible, advancing translational geroscience.
Area of Science:
- Geroscience and Gerotherapeutics
- Translational Medicine
- Aging Research
Background:
- Geroscience identifies molecular drivers of aging.
- Gerotherapeutics aim to counteract these drivers, mitigating chronic diseases and geriatric syndromes.
- Preventive gerotherapeutics face safety and endpoint challenges, delaying implementation in healthy aging populations.
Purpose of the Study:
- To review the gerotherapeutic benefits of specific drugs in disease management.
- To explore opportunities for advancing translational geroscience within contemporary healthcare.
- To contrast the challenges of preventive gerotherapeutics with disease-focused applications.
Main Methods:
- Literature review of gerotherapeutic applications.
- Analysis of challenges in preventive geroscience trials.
- Examination of disease management strategies incorporating gerotherapeutic agents.
- Discussion of Longevity Clinics and translational geroscience integration.
Main Results:
- Medications with gerotherapeutic properties are more readily trialed for treating existing diseases than for prevention.
- Risk-benefit assessments favor gerotherapeutic use when treating disease outweighs risks.
- Metrics for disease treatment efficacy are often more established than for healthspan extension.
Conclusions:
- Clarifying geroscience mechanisms in disease treatment accelerates translational geroscience.
- Preventive geroscience trials encounter significant encumbrances.
- Gerotherapeutic benefits of canakinumab, colchicine, and zoledronic acid in disease management are considered, alongside integration into contemporary care models.
